Sugi Predict

Sugi Predict / Compounds / SCHEMBL109128

SCHEMBL109128

SCHEMBL109128

O=C(O)c1ccc(F)c(Cl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.48
▸ CASP1 P29466 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CYP1A2 P05177 1/20 0.44
▸ KEAP1 Q14145 1/20 0.44
▸ NFE2L2 Q16236 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ GRIK1 P39086 2/20 0.42
▸ ALB P02768 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ ADRA2A P08913 1/20 0.41
▸ CLCN2 P51788 1/20 0.41
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAP2K1 Q02750 1/20 0.40
▸ ALOX15 P16050 2/20 0.39
▸ NR4A1 P22736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8829671 0.87 TSHR (0.61) TSHRCASP1SMN1; SMN2ALDH1A1TP53
SCHEMBL217628 0.85 TSHR (0.61) TSHRCASP1SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL32690872 0.85 TSHR (0.61) TSHRCASP1SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL29488311 0.84 TSHR (0.47) TSHRCASP1SMN1; SMN2CYP1A2KEAP1
SCHEMBL364951 0.84 TSHR (0.47) TSHRCASP1SMN1; SMN2CYP1A2KEAP1
SCHEMBL2579411 0.84 CES2 (0.50) TSHRCASP1SMN1; SMN2CYP1A2KEAP1
SCHEMBL31392754 0.84 CES2 (0.50) TSHRCASP1SMN1; SMN2CYP1A2KEAP1
SCHEMBL15878727 0.83 ALB (0.53) TSHRCASP1SMN1; SMN2CYP1A2KEAP1
Hydrochloric Acid SCHEMBL9860906 0.83 CES2 (0.48) TSHRCASP1SMN1; SMN2CYP1A2KEAP1
SCHEMBL6828586 0.83 ALB (0.53) TSHRCASP1SMN1; SMN2CYP1A2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247027-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-03-11 — — US disclosed
US-20240116930-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-04-11 — — US disclosed
US-11820770-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
US-20220213095-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-07-07 — — US disclosed
WO-2022138791-A1 EP2 ANTAGONIST 小野薬品工業株式会社 2022-06-30 — — WO disclosed
US-11225478-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2022-01-18 — — US disclosed
CN-110003200-B P2X7 modulators 詹森药业有限公司 2021-11-26 — — CN disclosed
US-20200325138-A1 P2X7 Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-15 — — US disclosed
US-10703749-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-07-07 — — US disclosed
EP-3309161-B1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR JANSSEN PHARMACEUTICA NV (BE) 2019-12-18 — — EP disclosed
EP-0764157-B1 BENZOPYRANS AND THEIR USE AS THERAPEUTIC AGENTS SMITHKLINE BEECHAM PLC (GB) 2002-01-02 — — EP disclosed
EP-1114821-A1 Benzopyrans and their use as therapeutic agents SMITHKLINE BEECHAM PLC (GB) 2001-07-11 — — EP disclosed
EP-1041980-A1 ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-11 — — EP disclosed
WO-1999033460-A1 ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1999-07-08 — — WO disclosed
US-5760074-A Treatment SMITHKLINE BEECHAM P.L.C. (GB) 1998-06-02 — — US disclosed
EP-0764157-A1 BENZOPYRANS AND THEIR USE AS THERAPEUTIC AGENTS SMITHKLINE BEECHAM PLC (GB) 1997-03-26 — — EP disclosed
EP-0600317-B1 Process for the preparation of halogenated benzoic acids HOECHST AG (DE) 1997-03-12 — — EP disclosed
US-5481032-A Process for the preparation of halogenated benzoic acids HOECHST AKTIENGESELLSCHAFT (DE) 1996-01-02 — — US disclosed
WO-1995034545-A1 BENZOPYRANS AND THEIR USE AS THERAPEUTIC AGENTS SMITHKLINE BEECHAM PLC (GB) 1995-12-21 — — WO disclosed
EP-0600317-A1 Process for the preparation of halogenated benzoic acids HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200325138-A1 P2X7 Modulators P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885
US-12247027-B2 P2X7 modulators P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885
US-11225478-B2 P2X7 modulators P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885
US-11820770-B2 P2X7 modulators P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885
US-20220213095-A1 P2X7 MODULATORS P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885
US-20240116930-A1 P2X7 MODULATORS P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885
US-10703749-B2 P2X7 modulators P2RX2, P2RX7, P2RY2 TSHR 2539/4885CASP1 716/4885SMN1; SMN2 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.